Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amphotericin b (amphotericin) -

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral le

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - amphotericin b (amphotericin) -

United States - English - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 10 ml - amphotericin b for injection usp should be administered primarily to patients with progressive, potentially life-threatening fungal infections. this potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. amphotericin b for injection usp is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), north american blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera absidia , mucor and rhizopus , and infections due to related susceptible species of conidiobolus and basidiobolus , and sporotrichosis. amphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. this product is contraindicated in those patients who have shown hypersensitivity to amphote

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: cholesterol; sodium succinate hexahydrate; dl-alpha-tocopherol; sucrose; hydrogenated soy phosphatidylcholine; sodium hydroxide; hydrochloric acid; 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium - amphotericin liposomal ran is indicated for:,? prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for,? the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see section 5.1 pharmacodynamic properties, clinical trials).,amphotericin liposomal ran is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment.,amphotericin liposomal ran is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium; dl-alpha-tocopherol; hydrogenated soy phosphatidylcholine; cholesterol; hydrochloric acid; sodium succinate hexahydrate; sucrose; sodium hydroxide - amphotericin liposomal rbx is indicated for:,? prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for,? the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see section 5.1 pharmacodynamic properties, clinical trials).,amphotericin liposomal rbx is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment.,amphotericin liposomal rbx is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; cholesterol; 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium; sodium succinate hexahydrate; sucrose; sodium hydroxide; dl-alpha-tocopherol; hydrochloric acid - amphotericin liposomal sun is indicated for:,? prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for,? the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see section 5.1 pharmacodynamic properties, clinical trials).,amphotericin liposomal sun is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment.,amphotericin liposomal sun is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - amphotericin b 50mg - powder for injection - 50 mg - active: amphotericin b 50mg excipient: cholesterol hydrochloric acid alpha-tocopherol distearoylphosphatidylglycerol phosphatidylcholines, soya, hydrogenated phosphatidylglycerols as sodium salt sodium hydroxide sodium succinate sucrose - ambisome is indicated for: · prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for · the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b. ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gilead sciences ireland uc - amphotericin b 50 mg - powder for dispersion for infusion - 50 mg - amphotericin b 50 mg - amphotericin b

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.